openPR Logo

Press Releases from Affiris (5 total)

04-30-2014 | Health & Medicine
Affiris

Parkinson's Vaccine – Top Experts Unite in European Consortium

EU support boosts development of therapeutic vaccines against Parkinson's and Multiple System Atrophy. AFFiRiS leads consortium. An international consortium of top European research teams has received significant EU funding for the development of therapeutic vaccines against Parkinson's Disease (PD) and Multiple System Atrophy (MSA). Led by the Austrian biotech company AFFiRiS AG, the consortium will use a novel tandem strategy to advance the development of two therapeutic vaccine candidates in parallel.

AFFiRiS - MIG-FONDS INCREASES INVESTMENT BY EURO 3 MILLION

Vienna, 25 September 2008. The successful progress of several vaccine programmes run by AFFiRiS GmbH has prompted investor MIG AG to increase its investment in the company. It has set up two new funds - MIG 5 and MIG 7 - to give private investors in Germany and Austria the opportunity to invest in this promising biotech company. The company decided to take this step for two reasons. First, to

AFFIRIS IN BIOTECH SPOTLIGHT 2008 - INDEPENDENT ANALYSIS CONFIRMS GLOBAL POTENTI …

Vienna, Austria, 28 April 2008: According to an analysis carried out by Lifescience-online, due to it\'s AFFITOME technology AFFiRiS GmbH could become a major player in the global pharmaceutical industry. After looking at data from a total of 67 European biotech companies, the study picked out the five firms with the most innovative approaches to therapy and most intensive R&D activities for closer analysis. AFFiRiS GmbH came top of this
04-17-2008 | Health & Medicine
Affiris

AFFIRIS DEVELOPS ALZHEIMER'S VACCINE

Vienna, 17. April 2008. The Viennese biotech company Affiris is today taking stock of the progress achieved to date in its clinical Alzheimer's vaccination programme. All the Alzheimer's patients treated so far as part of the toxicological trials have tolerated the treatment extremely well. As a result, Affiris is among the leading international centres in the race to develop the first causal immunotherapy for Alzheimer's disease. Due to the dramatic
07-19-2007 | Health & Medicine
Affiris

Affiris begins clinical testing of Alzheimer's vaccine

Vienna, 19th July 2007. The Alzheimer's vaccine known as Affitope AD01 from Affiris has now entered the clinical phase of its development. All relevant regulatory and statutory approvals have been secured and this innovative treatment is now being tested on humans for the first time. This development means that the 8.5 million-Euro venture capital finance agreement the company concluded with Munich-based MIG-Fonds in April 2006 has reached a key milestone